<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02521077</url>
  </required_header>
  <id_info>
    <org_study_id>MZ2015010</org_study_id>
    <nct_id>NCT02521077</nct_id>
  </id_info>
  <brief_title>Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer</brief_title>
  <official_title>Prospective Double Blind Study of the Effect of Intravenous High Dose Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Midwestern Regional Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Midwestern Regional Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a parallel-track, randomized study will observe whether intravenous ascorbic acid
      reduces the reported fatigue in women receiving adjuvant or neo-adjuvant chemotherapy for
      early stage breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Manufacturer unwilling to provide information needed for IND application.
  </why_stopped>
  <start_date type="Anticipated">May 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fatigue by self reported fatigue inventory questionnaire</measure>
    <time_frame>Day 8 of each 4-week treatment cycle.</time_frame>
    <description>Patients will complete the validated questionnaire Fatigue Symptom Inventory (FSI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatigue ( EORTC QLQ-FA13)</measure>
    <time_frame>Day 1 of each 4-week treatment cycle.</time_frame>
    <description>Patients will complete the validated questionnaire EORTC QLQ-FA13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue ( EORTC QLQ-FA13)</measure>
    <time_frame>Day 8 of each 4-week treatment cycle.</time_frame>
    <description>Patients will complete the validated questionnaire EORTC QLQ-FA13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue ( EORTC QLQ-FA13)</measure>
    <time_frame>Day 15 of each 4-week treatment cycle.</time_frame>
    <description>Patients will complete the validated questionnaire EORTC QLQ-FA13</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue by self reported fatigue inventory questionnaire</measure>
    <time_frame>Day 1 of each 4-week treatment cycle.</time_frame>
    <description>Patients will complete the validated questionnaire Fatigue Symptom Inventory (FSI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue by self reported fatigue inventory questionnaire</measure>
    <time_frame>Day 15 of each 4-week treatment cycle.</time_frame>
    <description>Patients will complete the validated questionnaire Fatigue Symptom Inventory (FSI)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Fatigue</condition>
  <arm_group>
    <arm_group_label>Odd Cycle Intravenous Ascorbic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women randomized to this study arm will receive intravenous ascorbic acid (50g in 500 ml sterile water) prior to their odd-numbered chemotherapy cycles. During the even-numbered chemotherapy cycles, these subjects will receive intravenous normal saline (0.9%).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Even Cycle Intravenous Ascorbic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women randomized to this study arm will receive intravenous ascorbic acid (50g in 500 ml sterile water) prior to their even-numbered chemotherapy cycles. During the odd-numbered chemotherapy cycles, these subjects will receive intravenous normal saline (0.9%).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>500 g ascorbic acid dissolved in 500 ml sterile water.</description>
    <arm_group_label>Odd Cycle Intravenous Ascorbic Acid</arm_group_label>
    <arm_group_label>Even Cycle Intravenous Ascorbic Acid</arm_group_label>
    <other_name>Vitamin C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Saline 0.9%</description>
    <arm_group_label>Odd Cycle Intravenous Ascorbic Acid</arm_group_label>
    <arm_group_label>Even Cycle Intravenous Ascorbic Acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status score â‰¤2;

          -  Diagnosed early stage breast cancer and scheduled to receive either adjuvant or
             neo-adjuvant chemotherapy;

          -  Willing to receive either intravenous ascorbic acid or normal saline;

          -  Willing to use an acceptable contraceptive method for the duration of the study and
             for 30 days following the last dose of study drug;

          -  Negative urine or serum pregnancy test within 2 weeks prior to receipt of study drug;

          -  Willing to complete all evaluation tools;

          -  Able to give informed consent to participate in the study; and

          -  Agree to avoid any additional supplemental ascorbic acid throughout the study.

        Exclusion Criteria:

          -  Diagnosed Glucose-6-phosphate dehydrogenase deficiency;

          -  Renal insufficiency (Blood Urea Nitrogen &gt;30 mg/dL, or Creatinine &gt;1.5 mg/dL);

          -  Unwillingness or mental incapacity to complete self-reported questionnaires;

          -  Active smoker; and

          -  Male sex
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Citrin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Midwestern Regional Medical Center</affiliation>
  </overall_official>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2015</study_first_submitted>
  <study_first_submitted_qc>August 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <last_update_submitted>June 23, 2017</last_update_submitted>
  <last_update_submitted_qc>June 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Midwestern Regional Medical Center</investigator_affiliation>
    <investigator_full_name>Dennis Citrin, MD</investigator_full_name>
    <investigator_title>Medical Oncologist</investigator_title>
  </responsible_party>
  <keyword>Ascorbic Acid</keyword>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

